a:5:{s:8:"template";s:11981:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0" name="viewport"/><title>{{ keyword }}</title>
<link href="https://fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700&amp;subset=latin%2Clatin-ext" id="nectar_default_font_open_sans-css" media="all" rel="stylesheet" type="text/css"/>
<link href="http://fonts.googleapis.com/css?family=Raleway%3A400%2C900%2C700%2C800%2C600%2C400italic%2C500&amp;subset=latin&amp;ver=1570357925" id="redux-google-fonts-salient_redux-css" media="all" rel="stylesheet" type="text/css"/>
</head>
<style rel="stylesheet" type="text/css">@charset "UTF-8";.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}.has-drop-cap:not(:focus):after{content:"";display:table;clear:both;padding-top:14px}.portfolio-items .custom-content .sharing-default-minimal .nectar-social[data-color-override=override] .nectar-social-inner a:not(:hover) i{opacity:1;color:#fff}.portfolio-items .custom-content .sharing-default-minimal .nectar-social-inner>.nectar-sharing:not(:hover){border-color:#fff}@media only screen and (max-width :690px){.col{margin-bottom:25px}}.nectar-social.hover.visible .nectar-social-inner a:not(:hover):nth-child(2){transition-delay:30ms}.nectar-social.hover.visible .nectar-social-inner a:not(:hover):nth-child(3){transition-delay:60ms}.nectar-social.hover.visible .nectar-social-inner a:not(:hover):nth-child(4){transition-delay:90ms}.nectar-social.hover.visible .nectar-social-inner a:not(:hover):nth-child(5){transition-delay:.12s}@font-face{font-family:FontAwesome;src:url(fonts/fontawesome-webfont.eot?v=4.2);src:url(fonts/fontawesome-webfont.eot?#iefix&v=4.2) format('embedded-opentype'),url(fonts/fontawesome-webfont.svg#fontawesomeregular?v=4.2) format('svg'),url(fonts/fontawesome-webfont.woff?v=4.2) format('woff'),url(fonts/fontawesome-webfont.ttf?v=4.2) format('truetype');font-weight:400;font-style:normal}.col{position:relative;display:block;float:left;width:100%}@media (min-width:690px){.col{margin-right:2%}}.col.col_last{margin-right:0}.col:last-child{margin-right:0}@media (min-width:690px){.span_3{width:23.5%}.span_9{width:74.5%}}a,body,div,header,html,nav,ul{margin:0;padding:0;border:0;font-size:100%;font:inherit;vertical-align:baseline}html{overflow-x:hidden;overflow-y:scroll;max-width:100%}body{max-width:100%;overflow-x:hidden;background:#fff;font-family:'Open Sans',sans-serif;color:#676767;position:relative}ul{list-style:none}header,nav{display:block}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}.container{margin:0 auto;position:relative}.container{max-width:880px}.row{position:relative}.col:after,.row:after{content:"";display:block;height:0;clear:both;visibility:hidden}.row{padding-bottom:24px}@media (min-width:690px){.span_3{width:23.5%}.span_9{width:74.5%}}body{font-size:14px;-webkit-font-smoothing:antialiased;font-family:'Open Sans';font-weight:400;line-height:26px}body:not(.nectar-no-flex-height){display:flex;flex-direction:column;min-height:100vh}body:not(.nectar-no-flex-height) #ajax-content-wrap{display:flex;flex-direction:column;flex-grow:1}a{color:#3555ff;text-decoration:none;transition:color .2s;-webkit-transition:color .2s}a:hover{color:inherit}.container .row:last-child{padding-bottom:0}ul{margin-left:30px;margin-bottom:30px}#header-outer nav>ul{margin:0}#header-outer{width:100%;top:0;left:0;position:fixed;padding:28px 0 0 0;background-color:#fff;z-index:9999;overflow:visible}#top #logo{width:auto;max-width:none;display:block;line-height:22px;font-size:22px;letter-spacing:-1px;color:#444;font-family:'Open Sans';font-weight:600}#top #logo:focus,#top #logo:hover{color:#000}#top{position:relative;z-index:9998;width:100%}#top .container .row{padding-bottom:0}#top nav>ul{overflow:visible;transition:padding .8s ease,margin .25s ease;min-height:1px;line-height:1px}#top nav>.buttons{transition:padding .8s ease}#header-outer #top nav>.buttons{right:0;height:100%;overflow:hidden}.sf-menu{line-height:1;float:left;margin-bottom:30px}.sf-menu{list-style:none outside none;margin:0;padding:0;z-index:10}.sf-menu{line-height:1}#top .span_9{position:static}#header-outer[data-megamenu-rt="1"].no-transition #top nav>ul>li[class*=button_bordered]>a:not(:hover):before,#header-outer[data-megamenu-rt="1"].no-transition.transparent #top nav>ul>li[class*=button_bordered]>a:not(:hover):before{-webkit-transition:none!important;transition:none!important}#header-outer:not([data-format=left-header]) #logo{transition:margin .32s ease}@media only screen and (min-width:1000px){#header-outer:not([data-format=left-header]){padding-top:0}#header-outer:not([data-format=left-header]) #top>.container>.row,#header-outer:not([data-format=left-header]) #top>.container>.row nav,#header-outer:not([data-format=left-header]) #top>.container>.row nav>ul{display:-webkit-flex;display:-ms-flexbox;display:flex}#header-outer:not([data-format=left-header]) #top .span_3,#header-outer:not([data-format=left-header]) #top .span_9{display:-webkit-flex;display:-ms-flexbox;display:flex;float:none;width:auto}#header-outer:not([data-format=left-header]) #top nav>.buttons{overflow:visible;height:auto}#header-outer:not([data-format=left-header]) #top nav>ul{float:none;display:inline-block;vertical-align:middle}}@media only screen and (max-width:999px){#top .col.span_9{text-align:right;line-height:0}}#header-outer .row .col.span_3,#header-outer .row .col.span_9{width:auto}#header-outer .row .col.span_9{float:right}.col{position:relative;float:left}@media all and (-ms-high-contrast:none){::-ms-backdrop{width:100%}}.post-area.standard-minimal .post .article-content-wrap .meta-category a:not(:hover),.post-area.standard-minimal .post .article-content-wrap .meta-comment-count a:not(:hover){color:#aaa}.post-area.standard-minimal .post .article-content-wrap .meta-category:not(:hover) i,.post-area.standard-minimal .post .article-content-wrap a:not(:hover) i:not(.loved){color:#c1c1c1}.post-area.standard-minimal .post .article-content-wrap .flex-direction-nav a:not(:hover) i:not(.loved),.post-area.standard-minimal .post .article-content-wrap .meta-category:not(:hover) .flex-direction-nav i{color:#fff}@media only screen and (min-width :690px) and (max-width :999px){.container{max-width:600px}}#footer-outer{color:#ccc;position:relative;z-index:10;background-color:#252525}#slide-out-widget-area-bg{-webkit-backface-visibility:hidden;background-color:rgba(0,0,0,.8);position:fixed;height:1px;width:1px;opacity:0;left:0;top:0;z-index:9996}#slide-out-widget-area-bg .bg-inner{width:100%;height:100%;background-color:rgba(0,0,0,.8)}#slide-out-widget-area-bg.fullscreen-alt{padding:20px;background-color:transparent;transform:none!important;-webkit-transform:none!important;will-change:opacity,padding}body #slide-out-widget-area-bg.fullscreen-alt{transition:padding .3s cubic-bezier(.215,.61,.355,1),opacity .25s ease;-webkit-transition:padding .3s cubic-bezier(.215,.61,.355,1),opacity .25s ease}body #slide-out-widget-area-bg.fullscreen-alt.solid{opacity:0}#slide-out-widget-area-bg.fullscreen-alt{transform:translateY(-100%);-webkit-transform:translateY(-100%);opacity:1;display:none}#slide-out-widget-area-bg.fullscreen-alt{display:block;left:-100%}#slide-out-widget-area-bg.fullscreen-alt.solid{opacity:1}@font-face{font-family:'Open Sans';font-style:normal;font-weight:300;src:local('Open Sans Light'),local('OpenSans-Light'),url(https://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN_r8OXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(https://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFW50e.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:600;src:local('Open Sans SemiBold'),local('OpenSans-SemiBold'),url(https://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UNirkOXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:700;src:local('Open Sans Bold'),local('OpenSans-Bold'),url(https://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN7rgOXOhs.ttf) format('truetype')}@media only screen and (min-width:1300px){.container{max-width:1100px}}@media only screen and (min-width :690px) and (max-width :999px){.span_3,.span_9{width:100%;margin-left:0}.col{margin-bottom:25px}#header-outer .col{margin-bottom:0;margin-right:0}.container{max-width:600px}}@media only screen and (max-width :690px){.container{max-width:320px}.col{margin-bottom:25px}#header-outer .col{margin-bottom:0}}@media only screen and (min-width :1px) and (max-width :999px){body #header-outer{margin-bottom:0;padding:12px 0}body #header-outer{position:relative}#header-outer #logo{top:0;left:0}#top .col.span_3{left:0;top:0;z-index:100;width:100%}#top .col.span_3{position:relative}#header-outer #top .col.span_3{line-height:0}#header-outer #top .col.span_3 #logo{vertical-align:middle}#top .col.span_9{margin-left:0;margin-bottom:0;width:100%!important;float:none;z-index:100;position:static}#top .col.span_9{min-height:0;width:auto!important;position:absolute!important;right:0;top:0;z-index:2000;height:100%}#header-outer #top nav>ul{width:auto;padding:15px 0 25px 0;margin:0 auto 0 auto;z-index:100000;position:relative}#header-outer #top nav{display:none!important}#top{height:auto!important}}@media only screen and (max-width:321px){.container{max-width:300px}}@media only screen and (min-width:480px) and (max-width:690px){body .container{max-width:420px}}@media screen and (max-width:782px){body{position:static}}.container:after,.container:before,.row:after,.row:before{content:" ";display:table}.container:after,.row:after{clear:both} body a{color:#22bbf2}#slide-out-widget-area-bg.fullscreen-alt .bg-inner{background-color:#22bbf2}body{background-color:#fff}body{color:#000}body #slide-out-widget-area-bg{background-color:rgba(0,0,0,.4)}@media only screen and (min-width:1000px){#header-outer #logo{margin-top:28px;margin-bottom:28px;position:relative}}body #header-outer{background-color:rgba(0,0,0,.1)}body{font-family:Raleway;font-size:16px;line-height:30px;font-weight:400}@media only screen and (max-width:1300px) and (min-width:1000px){body{font-size:16px;line-height:30px}}@media only screen and (max-width:999px) and (min-width:690px){body{font-size:16px;line-height:30px}}@media only screen and (max-width:690px){body{font-size:16px;line-height:30px}}@font-face{font-family:Raleway;font-style:italic;font-weight:400;src:local('Raleway Italic'),local('Raleway-Italic'),url(https://fonts.gstatic.com/s/raleway/v14/1Ptsg8zYS_SKggPNyCg4TYFv.ttf) format('truetype')}@font-face{font-family:Raleway;font-style:normal;font-weight:400;src:local('Raleway'),local('Raleway-Regular'),url(https://fonts.gstatic.com/s/raleway/v14/1Ptug8zYS_SKggPNyC0ISg.ttf) format('truetype')}@font-face{font-family:Raleway;font-style:normal;font-weight:500;src:local('Raleway Medium'),local('Raleway-Medium'),url(https://fonts.gstatic.com/s/raleway/v14/1Ptrg8zYS_SKggPNwN4rWqZPBQ.ttf) format('truetype')}  </style>
<body class="nectar-auto-lightbox ascend wpb-js-composer js-comp-ver-5.7 vc_responsive">

<div id="header-space"></div>
<div id="header-outer">
<header id="top">
<div class="container">
<div class="row">
<div class="col span_3">
<a class="no-image" href="#" id="logo">
{{ keyword }}
</a>
</div>
<div class="col span_9 col_last">
<nav>
<ul class="sf-menu">
</ul>
<ul class="buttons sf-menu" data-user-set-ocm="off">
</ul>
</nav>
</div>
</div>
</div>
</header>
</div>
<div id="ajax-content-wrap">
{{ text }}
<div id="footer-outer">
{{ links }}
</div>
<div class="fullscreen-alt solid" id="slide-out-widget-area-bg">
<div class="bg-inner"></div> </div>
<div class="inner-wrap">
<div class="inner">
{{ keyword }} 2021
</div>
</div> 
</div> 
</body>
</html>";s:4:"text";s:19496:"Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share. The Bioinformatics Senior Research Associate is responsible for designing and troubleshooting PCR-based assays for use with the GenMark Dx ePlex® platform. Last Name* Last name required. Shares in GenMark soared as much as 32% Thursday to hit a record high of $22.19. Description. Our growing infectious disease menu includes: Blood Culture Identification (BCID) Panels. Free Soda, Lot of nice friendly people. Segmentation . Our work atmosphere is dynamic, fast-paced, and patient-focused. 91 GenMark Diagnostics reviews. View all jobs at GenMark Diagnostics Report Job. Explore working for GenMark Diagnostics and see what it's like to work in the area. Manufacturing. Feb 11, 2021. Our â¦ See insights on GenMark Diagnostics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. A free inside look at company reviews and salaries posted anonymously by employees. Free, fast and easy way find a job of 831.000+ postings in Carlsbad, CA and other big cities in USA. That is because â¦ The writer will create content on the general strategies of market players. Management will hold a conference call to review the company's. Third Quarter 2020 Highlights. CARLSBAD, Calif. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Join GenMark, where you can be a hero too At GenMark, weâre changing the diagnostics landscape, combining out-of-the-box thinkers and game-changing technology to revolutionize patient care. Report Job. GenMark Diagnostics | 10,091 followers on LinkedIn. Free Soda, Lot of nice friendly people. GenMark Diagnostics, Inc. operates as a molecular diagnostics company focused on developing and commercializing its biomarker detection technology. Industry. Salaries, reviews and more - all posted by employees working at GenMark Diagnostics. See what employees say it's like to work at GenMark Diagnostics. (RTTNews) - Swiss drug major Roche Group (RHHBY) announced Monday its agreement to acquire GenMark Diagnostics (GNMK) for $24.05 per share in an all-cash transaction. GenMark Diagnostics provided pay range This range is provided by GenMark Diagnostics. Email Alerts. We encourage teamwork, while reinforcing the importance of individuality, and foster an entrepreneurial spirit. Health Care. GenMark Diagnostics has 437 employees across 33 locations and $171.55 M in annual revenue in FY 2020. GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. I have been working at GenMark Diagnostics full-time for more than a year. Star Star Star Star Star 111 Reviews. Mr. Gleeson remained an integral part of GenMarkâs growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. The More You Detect, The Better You Protect. Star Star Star Star Star 18 Reviews. Description. Best Jobs in the UK 2021 NEW! GenMark is working with a financial adviser as it fields interest from other medical diagnostics companies, the people said, asking not to be identified because the deliberations are private. Mar 15, 2021. Genmark Automation Jobs. Star Star Star Star Star 25 Reviews. Select a reason for reporting this job. The ideal candidate must be able to work in a collaborative research and IVD product development environment and demonstrate ability to analyze sequence data to drive assay development. Performing lab duties while maintaining associated health and safety guidelines while maintaining inventory of laboratory reagents and supplies. GenMark Diagnostics Surges 7% on Preliminary 4Q Results. Select a reason for reporting this job. Toll-Free: 1.800.373.6767 Phone: 1.760.448.4300 Fax: 1.760.448.4301 GenMarkâs ePlex ® Blood Culture Identification (BCID) Panels provide broad coverage of organisms that can lead to sepsis along with their resistance genes. This corresponds to a total transaction value of approximately US$ 1.8 billion on a fully diluted basis. See what employees say about what it's like to work at GenMark Diagnostics. GenMark Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, announced that it has commenced an underwritten public offering of shares of its common stock. Roche and GenMark Diagnostics have entered into a definitive merger agreement for Roche to fully acquire GenMark for approximately $1.8 billion, or $24.05 per share, in an all-cash transaction, according to a news release from Roche. The Swiss healthcare company, Roche, entered a definitive merger agreement to purchase GenMark for a total transaction value of approximately $1.8 billion on a fully diluted basis. Careers At GenMark Diagnostics. GenMark Diagnostics, Inc. (NASDAQ:GNMK) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates Yahoo 10/30 07:53 ET GenMark Diagnostics Inc (GNMK) Q3 2020 Earnings Call Transcript We deliver innovative, diagnostic solutions that improve the lives of patients and their families and are proud to be one of the heroic diagnostic companies that is in this fight against COVID-19. This job is offensive or discriminatory This job appears to â¦ Salaries, reviews, and more - all posted by employees working at GenMark Diagnostics. GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, has been selected by Vidant Health as its primary provider of rapid diagnostic testing. GenMark Diagnostics Careers . GenMark Diagnostics | 11.445 Follower auf LinkedIn Transforming Multiplex Molecular Testing & Diagnostics | GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Negative Outlook. Feb 11, 2021. Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Apply to Infectious Disease Physician, Chemist, Shift Leader and more! Pros. Industry. Jobs available in Carlsbad CA and San Francisco CA. GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems. Submit Your Information. Your actual pay will be based on your skills and experience â talk with your recruiter to learn more. 91 GenMark Diagnostics reviews. Shareholder Anthony Franchi sued GenMark Diagnostics Inc. and the members of its board of directors for violations of the Securities Exchange Act of 1934 on Monday. Shares in Genmark Diagnostics Inc are currently trading at $24.04 and the price has moved by 0.187k% over the past 365 days. Disapproves of CEO. GenMark is a leading provider of automated, multiplex molecular diagnostic testing systems. This is the GenMark Diagnostics company profile. Roche Holding AG (OTCMKTS: RHHBY) will fully acquire GenMark Diagnostics Inc. (NASDAQ: GNMK) at a price of $24.05 USD per share in an all-cash transaction, the company announced on March 15. Agilent Technologies Jobs. Shawn Hall is a Systems Support Engineer at GenMark Diagnostics based in Carlsbad, California. Annual report which provides a comprehensive overview of the company for the past year. In terms of relative price strength - which takes into account the overall market trend - the Genmark Diagnostics Inc price has moved by 0.119k% over the past year. Investors Overview. GenMarkâs ePlex®: The True Sample-to-Answer Solutionâ¢ is designed to optimize laboratory â¦ Fujirebio Diagnostics Jobs. Report Job. Login to the Customer Resource Center to view SDS Sheets, Package Inserts, Worksheets, Training Presentations and Brochures. GenMark Diagnostics believes that its culture is at the center of what makes it a rewarding place of employment. Genmark Diagnostics Jobs, Employment in Carlsbad, CA 2021 | Indeed.com Assignee: GenMark Diagnostics, Inc. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Favoratism, Supervisors are unfriendly and unprofessional. Roche and GenMark Diagnostics have entered into a merger agreement in which Roche will fully acquire GenMark for $1.8 billion. From Capital Market Laboratories Apr 17, 2021. Pros. 10-K. Filing Date. Acquisition Rumors Send GenMark Diagnostics Shares into Orbit. Get insights about the company culture, growth opportunities, work life balance and more at Careerbliss.com View %COMPANY_NAME% GNMK investment & stock information. Report Job. GenMark Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, announced that the company plans to participate in two upcoming investor conferences. NEW YORK â Roche said on Monday that it plans to acquire GenMark Diagnostics for approximately $1.8 billion in cash. Roche to Acquire GenMark Diagnostics for $1.8 Billion in Cash MT Newswires 03/15 14:35 ET GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagnostics acquisition by F. Hoffman La-Roche Ltd. Shares of GenMark Diagnostics rose 6.6% in Tuesdayâs pre-market trading as the company announced an 84% year-over-year jump in its preliminary fourth-quarter revenue to about $50 million. Address Carlsbad, CA. Search and apply for the latest Associate product development manager jobs in Carlsbad, CA. The test provides results in less than two hours for more than 20 viruses and bacteria that cause respiratory infections, including COVID-19, flu, bronchitis, and the common cold. Published. Utilizing GenMark's proprietary eSensor detection technology, GenMark's eSensor XT-8 system and ePlex sample-to-answer systems are designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. Favoratism, Supervisors are unfriendly and unprofessional. GenMark Diagnostics is committed to addressing the need to improve patient care through the design and development of comprehensive multiplex panels. Cons. Open Positions. Competitive salary. Carlsbad-based GenMark Diagnostics received emergency authorization from the U.S. Food and Drug Administration for its COVID-19 test, which means that medical labs can use it â¦ You may automatically receive GenMark Diagnostics, Inc. financial information by email. I have been working at GenMark Diagnostics full-time for more than a year. Salaries, reviews, and more - all posted by employees working at GenMark Diagnostics. Our work atmosphere is dynamic, fast-paced, and patient-focused. Swiss pharma company Roche has entered into a definitive merger agreement to acquire GenMark Diagnostics for approximately $1.8bn. January 2021âGenMark Diagnostics received FDA emergency use authorization for its ePlex Respiratory Pathogen Panel 2. Please enter your preferences for email notifications below and click "Submit". Roche and GenMark Diagnostics have entered into a definitive merger agreement for Roche to fully acquire GenMark for approximately $1.8 billion, or $24.05 per share, in an all-cash transaction, according to a news release from Roche. Scott Mendel is President/CEO at Genmark Diagnostics Inc. See Scott Mendel's compensation, career history, education, & memberships. GenMark Diagnostics, Inc. United States: Scientist, Product Technical Support: GenMark Diagnostics, Inc. Carlsbad, CA: $39K-$75K: Associate Supervisor, Manufacturing: GenMark Diagnostics, Inc. Carlsbad, CA: $37K-$70K: Director, Lifecycle Management: GenMark Diagnostics, Inc. Carlsbad, CA: $97K-$226K: Document Control Specialist I, Product Support: GenMark Diagnostics, â¦ See what employees say it's like to work at GenMark Diagnostics. The low-stress way to find your next genmark diagnostics job opportunity is on SimplyHired. GenMark is committed to best-in-class service and support, and provides customers with an expert network of in-house specialists, customer service, and field support teams. We deliver innovative, diagnostic solutions that improve the lives of patients and their families and are proud to be one of the heroic diagnostic companies that is in this fight against COVID-19. Roche to Acquire GenMark Diagnostics for $1.8B. Select a reason for reporting this job. Report Job. Find out what works well at GenMark Diagnostics from the people who know best. Second Quarter 2020 Highlights. Inventors: Michael Leonard Wood, Aviva Ruth Jacobs. Mar 2, 2020. 83 GenMark Diagnostics reviews. GenMark Diagnostics, Inc. A summary of Expert Comments about GenMark Diagnostics, Inc. is currently unavailable. Smith Collection/Gado/Getty Images. View all jobs at GenMark Diagnostics Report Job. Apply to Environmental Health Officer, Technician, Senior Maintenance Technician and more! GenMark Diagnostics shares (GNMK) are listed on the NASDAQ and all prices are listed in US Dollars. ePlex Panels. We currently have 2 open jobs at GenMark Diagnostics. See salaries, compare reviews, easily apply, and get hired. Careers at GenMark Heroes work here! Mar 15, 2021 2:21AM EDT. March 16, 2021âRoche and GenMark Diagnostics have entered into a definitive merger agreement for Roche to acquire GenMark for about $1.8 billion on a fully diluted basis. 17 days ago GenMarkâs stock jumped from Fridayâs close of $18.50 to $23.90 in early trading this morning. April 21, 2021 GenMark Investor Wants Records On $1.8B Roche Deal March 15, 2021 DLA Piper, Sidley Guide $1.8B Deal For Disease Testing Biz Stay ahead of the curve 32 Genmark Diagnostics jobs available in Carlsbad, CA on Indeed.com. ZURICH, March 15 (Reuters) - Roche said on Monday it would buy GenMark Diagnostics , a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal. GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021. Email* Email required. Come join the team thatâs changing the molecular diagnostics landscape and revolutionizing patient care! The Companyâs electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Learn More. Leads are dump and unexperienced and its nowhere to find when you need them. 91 GenMark Diagnostics reviews. Select a reason for reporting this job. Learn More. Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.. Roche said it will acquire the company for $24.05 per share. Search 47 job openings at GenMark Diagnostics. Date of Patent: June 2, 2020. GenMark Diagnostics is a medium health care company with 308 employees and an annual revenue of $50.6M that is headquartered in Carlsbad, CA. Please enter a valid email address. Heroes work here! Check out GenMark Diagnostics reviews posted by real employees. Careers At GenMark Diagnostics. GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results â¦ Report Job. Resize icon. February 11, 2021. WHAT YOU'LL DO AT GENMARK! View all jobs at GenMark Diagnostics Report Job. Negative Outlook. GenMark Diagnostics, Inc. (NASDAQ:GNMK) Q3 2020 Earnings Conference Call October 28, 2020, 04:30 PM ET Company Participants Leigh Salvo - â¦ GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, has been selected by Vidant Health as its primary provider of rapid diagnostic testing. LEARN MORE GenMark Diagnostics, Inc. GenMark Diagnostics, Inc. (GNMK) CEO Hany Massarany on Q4 2018 Results - Earnings Call Transcript Feb. 21, 2019 GenMark Diagnostics (GNMK) 37th Annual J.P. Morgan Healthcare Conference - Slideshow DiaSorin Jobs. BioFire Diagnostics generates $1.1B more revenue than GenMark. Roche purchases shares in tender offer for GenMark Diagnostics, Inc. Basel, 22 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics, Inc. today announced that Rocheâs wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common â¦ If you suffered a loss on your GenMark Diagnostics, Inc. investments or would like to inquire about joining an action to recover your loss under the feder Blood Culture Identification (BCID) Panels. Poor management. 62 Genmark Diagnostics jobs available on Indeed.com. Dr. Kayyem currently serves as a strategic advisor to GenMarkâs management and Board. The Techncial Trigger Driven Stock Trade in GenMark Diagnostics Inc (NASDAQ:GNMK) . GenMark Diagnostics, Inc. GNMK has moved higher as of late, but there could definitely be trouble on the horizon for this company. We've calculated that the average salary at GenMark Diagnostics is $67K based on 61 user-submitted salaries A total of 4 GenMark Diagnostics employees gave GenMark Diagnostics â¦ View all jobs at GenMark Diagnostics Report Job. Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample. Shareholder Anthony Franchi sued GenMark Diagnostics Inc. and the members of its board of directors for violations of the Securities Exchange Act of 1934 on Monday. Roche Acquires GenMark in $1.8 Billion Deal. 26 genmark diagnostics jobs available. Like GenMark, BioFire Diagnostics also operates in the Biotechnology industry. Sirisha Bhogaraju. First Name* First name required. Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics (NASDAQ: GNMK) announced that they have entered into a definitive merger agreement for Roche to fully acquire GenMark at a price of US$ 24.05 per share in an all-cash transaction. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. GenMark Diagnostics Reports Third Quarter 2020 Results - read this article along with other careers information, tips and advice on BioSpace GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2020. Full-time, temporary, and part-time jobs. Select a reason for reporting this job. Publication number: 20200156065. eSensor technology is highly specific for the target biomarker and is not based on fluorescent or optical detection. Through the acquisition, Roche aims to expand its portfolio of molecular diagnostics with GenMarkâs expertise in syndromic testing. GenMark Diagnostics (NASDAQ:GNMK) says Hany Massarany has stepped down as President and CEO and as a board member, effective immediately. ";s:7:"keyword";s:27:"genmark diagnostics careers";s:5:"links";s:904:"<a href="https://royalspatn.adamtech.vn/ucraj/netherlands-vs-austria-results">Netherlands Vs Austria Results</a>,
<a href="https://royalspatn.adamtech.vn/ucraj/pavers-denver-colorado">Pavers Denver Colorado</a>,
<a href="https://royalspatn.adamtech.vn/ucraj/can-my-current-employer-see-my-resume-on-ziprecruiter">Can My Current Employer See My Resume On Ziprecruiter</a>,
<a href="https://royalspatn.adamtech.vn/ucraj/red-golden-pheasants-for-sale-craigslist">Red Golden Pheasants For Sale Craigslist</a>,
<a href="https://royalspatn.adamtech.vn/ucraj/pictures-of-physical-change-and-chemical-change">Pictures Of Physical Change And Chemical Change</a>,
<a href="https://royalspatn.adamtech.vn/ucraj/ap-euro-multiple-choice-study-guide-quizlet">Ap Euro Multiple Choice Study Guide Quizlet</a>,
<a href="https://royalspatn.adamtech.vn/ucraj/elegance-good-crossword-clue">Elegance Good Crossword Clue</a>,
";s:7:"expired";i:-1;}